You're Telling Us... - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

You're Telling Us...
PharmTech's polls feature user feedback on issues facing the pharmaceutical industry.


Pharmaceutical Technology


Alexis Brekke
The editors at Pharmaceutical Technology worked hard last month developing ways to improve our online offerings, from the launch of a new Equipment & Processing report to a redesigned weekly enewsletter (ePT) to the creation of PharmTech Polls. This new feature on pharmtech.com is a way to give you, our readers, a voice online and allow you to weigh in on important industry topics.

So far, voters have shared their definitions of "design space," predictions for the future of inhalation drug delivery, concerns about over-the-counter (OTC) children's medications, options for reforming the US Food and Drug Administration's foreign inspections process, speculations on the industry's focus in 2008, and more.

Your feedback is often honest and insightful. One user described "design space" as "just a new buzzword for defining the acceptable range of a product and process, which is something an optimization program should have done for many years now."

In response to our question on standardizing dosing devices for OTC children's medications, which all respondents supported, one user said these medications and devices should be sold in the same manner as pseudoephedrine formulations—directly by a pharmacist.

A comment stemming from our inhalation delivery poll says "the science to deliver macromolecules for systemic absorption has been pushed too rapidly by a selected few in the 'aerosol delivery' scientific community," warning that the implications of this delivery method on the lungs are not completely understood.

We look forward to hearing more input from you. Share your views with us at pharmtech.com/polls.

Alexis Brekke is an assistant editor of Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here